The latest domestic approval time and application prospects of odevixibat

Odevixibat (Odevixibat) is an oral small molecule intestinal-selective I type bile acid transporter (IBAT) inhibitor, mainly used for treatment Progressive familial cholestasis in children (PFIC) can reduce the accumulation of bile acids in the liver, improve itching symptoms and abnormal liver function. In China, the drug has been officially approved for marketing, providing a new treatment option for PFIC patients. Although it is on the market, it is not yet included in the medical insurance system, so patients need to pay for it at their own expense.

In overseas markets, the specifications of the original drug Odesibate are 200mcg*30 tablets, and the price is approximately more than 40,000 yuan (affected by exchange rate fluctuations). The efficacy of the original drug has been clinically verified and the indications are clear. It is one of the important drugs in the world for the treatment of PFIC and related cholestasis. Due to the high price, domestic patients have a greater financial burden when treated with original drugs.

There are also many generic drugs of odexibat on the overseas market, such as produced by Lucius in Laos400mcg*30 tablets, priced at about RMB 3,000; and The price of 200mcg30 capsules or 1200mcg30 capsules produced by Laos ASEAN Pharmaceutical is about more than 500 yuan (may fluctuate due to exchange rate). The ingredients of these generic drugs are basically the same as those of the original drugs, and the efficacy is similar, but the price is more economical, making them an option for some patients.

The domestic launch of odexibat brings new treatment hope to patients with PFIC and other cholestasis-related diseases. PFIC Its targeting of the bile acid transport mechanism can effectively relieve itching, improve liver function indicators, and delay the progression of liver damage. In the future, with the accumulation of clinical experience and optimization of medical insurance policies, the drug has promising domestic application prospects and is expected to become one of the core drugs in the management of cholestatic diseases in children and adults.

Reference materials:https://www.drugs.com/